Physician profile
Neelima Ryali
NPI 1508874918
$854.32
in general payments reported to CMS, 2019-2025
13 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2022: $56.45 · 2023: $21.06 · 2024: $460 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $174.57 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $167.98 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $163.07 | 2024-2025 | Uplizna, Evenity, Prolia |
| Abbvie INC. | $76.66 | 2024 | |
| Edwards Lifesciences Corporation | $56.45 | 2022 | |
| Biogen, INC. | $50.11 | 2024-2025 | Leqembi, Vumerity |
| Pfizer INC. | $33.50 | 2024 | |
| Ucb, INC. | $32.62 | 2024 | Fintepla, Rystiggo |
| Inspire Medical Systems, INC. | $25.98 | 2024 | Inspire |
| Dexcom, INC. | $21.06 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $18.73 | 2025 | |
| Sumitomo Pharma America, INC. | $18.69 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neelima Ryali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.